New Radiochemistry Facility Fully Operational

Quotient Bioresearch has commenced operations at its new radiochemistry facility located near to Cardiff Bay in Wales, with shipments of radiolabelled products under way and the transfer of staff from a former site
completed. Following its acquisition of Amersham Radiolabelling Services from GE Healthcare in June 2009, the company moved to a new site known as ‘The Old Glassworks’, where a bespoke service for the custom synthesis of carbon-14 and tritium labelled compounds and the manufacture of custom radiolabelled drugs for use in both pre-clinical and clinical settings are offered to customers worldwide.

Paul Cowan, Chairman & Chief Executive Officer, Quotient, said: “With the opening of the new Cardiff facility, we have made a significant investment to support the product development needs of our pharmaceutical,
biotechnology and agrochemicals clients. We have invested significantly in technology that will make the business operate sustainably and allow our expert chemists to efficiently deliver the highest quality products to our clients. With almost one-third of all registered drugs on the market today having been radiolabelled by Quotient chemists, the opening of The Old Glassworks will allow us to continue to expand on this record of success."

Stephen Lewinton, Managing Director, Quotient Chemistry and Metabolism, said: "The new facility demonstrates our commitment to the radiochemicals business and allows us to build on our fully integrated carbon-14-enabled drug development services (including Synthesis-to- Clinic). Quotient remains focused on meeting the needs of its clients for cost-effective custom radiosynthesis services."